Vector Sciences & Therapeutics corrects Verlytix launch release details

• Vector Science & Therapeutics issued a correction to its Aug. 18 release on Verlytix’s launch.
• The amended version adds that Verlytix is applying its analytical and quality testing platform to peptide testing supporting Vector’s peptide portfolio.
• The correction also clarifies Verlytix’s positioning as a related company to LyoGenesis Manufacturing alongside its existing pharmaceutical testing business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608180755PR_NEWS_USPR_____LA28423) on August 18, 2026, and is solely responsible for the information contained therein.